NKILT Therapeutics
Henri Bayle has a diverse work experience in the pharmaceutical and medical field. Henri is currently the Chief Technology Officer and Chief Development Officer at NKILT Therapeutics since July 2021. Prior to that, they worked at Bellicum Pharmaceuticals, Inc. where they held various roles including Vice President of Research, Senior Director, and Director from November 2014 to March 2023. Before joining Bellicum Pharmaceuticals, Inc., Henri worked at Baylor College of Medicine as an Assistant Professor from 2007 to 2014. Henri also worked at Stanford University School of Medicine as a Research Scientist from 2001 to 2006.
Henri Bayle has a Bachelor of Science (B.Sc.) degree in Genetics from the University of Alberta. Later, they pursued a Doctor of Philosophy (Ph.D.) in Molecular Biology at Princeton University. Currently, Henri is a Postdoctoral Fellow at the Stanford University School of Medicine, specializing in the field of Pathology.
This person is not in any teams
This person is not in any offices
NKILT Therapeutics
NKILT Therapeutics is a new cell therapy biotech coming out of stealth mode, that is developing a novel approach of targeting NK cells to fight hard to treat leukemias and solid tumors. Our platform will be based on an allogeneic approach using armored NK cells, focused on a new undisclosed target. Our NK cells will not only directly kill cancer cells, but will also activate innate immunity and directly target the tumor’s defense mechanisms.
Employees
1-10